This kit is used for the detection of hotspot mutations in exons 2, 3 and 4 of the human NRAS gene. The kit uses DNA as the test sample to provide qualitative assessment of the mutation status.

Features: easy operation, less time consuming; reliable results, intuitive interpretation; high sensitivity, sample saving. Accurately detects mutations down to 1%. Only 1-3 tumor tissue sections are required.

NRAS gene is a common oncogene in human tumors. Mutations in this gene are common in a variety of malignant tumors, with mutation rates ranging from 1 to 6% in patients with colorectal cancer.NRAS mutations are predominantly located in exons 2, 3, and 4.Patients with NRAS mutations have significantly reduced sensitivity to EGFR monoclonal antibodies, primarily cetuximab.Three large clinical studies at the 2013 CSCO Annual Meeting pointed out the need for clinicians to know more and more detailed genetic backgrounds of patients prior to treating mCRC patients with anti-EGFR monoclonal antibodies (panitumumab/cetuximab) in combination with chemotherapy. monoclonal antibody (panitumumab/cetuximab) in combination with chemotherapy for mCRC patients, clinicians need to know more and more details about the patients' genetic backgrounds, not only testing for the mutation hotspot exon 2 of the KRAS gene, but also testing for other exons and the NRAS gene. Patients who undergo such more detailed testing and selection are the ones who will benefit more from anti-EGFR monotherapy. on December 30, 2013, Merck Serono, in conjunction with the European Medicines Agency (EMA) and the United Kingdom's Medicines Control Regulatory Agency (MHRA), issued a notice to healthcare professionals stating that the therapeutic indications for cetuximab (eptifibatide) were updated to include the requirement for clarification of wild-type prior to treatment with cetuximab, and the need to identify the wild-type prior to treatment with cetuximab. The updated indications for cetuximab (epirubicin) suggest the importance of clarifying the status of wild-type RAS (exons 2, 3 and 4 of KRAS and NRAS) prior to treatment with cetuximab.